<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285583</url>
  </required_header>
  <id_info>
    <org_study_id>WN29852</org_study_id>
    <secondary_id>TRO19622 CL E Q 1425-1</secondary_id>
    <nct_id>NCT01285583</nct_id>
  </id_info>
  <brief_title>Safety Extension Study of TRO19622 in ALS</brief_title>
  <official_title>An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the assay is to assess the safety of TRO19622 330 mg QD as add-on therapy to
      riluzole 50 mg bid in the treatment of patients suffering from ALS, after completion of the
      preceding clinical trial (TRO19622 CL E Q 1015-1) in an open label extension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Entry of a patient into this safety study is intended to occur immediately after the patient
      has finished participating in the preceding efficacy study (Protocol TRO19622 CL E Q 1015-1).

      The Investigator will explain to the patients the nature of this open-label safety study, its
      procedures, requirements and restrictions so as to obtain their written informed consent.

      Each patient will be treated with olesoxime (TRO19622) until the results of the double-blind
      trial become available with a maximum of 15 months.

      Follow-up visits will take place every 3 months (+/- 2 weeks).

      Safety assessments will be performed at all visits (every 3 months).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure will be the safety assessment.</measure>
    <time_frame>Safety assessment will be calculated from the date of enrollment for a maximum of 15 months.</time_frame>
    <description>safety criteria will be:
Occurrence of AEs,
Physical examination,
Laboratory tests,
Vital signs and ECG,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures</measure>
    <time_frame>Every 3 month, from the date of enrollment for a maximum of 15 months.</time_frame>
    <description>Secondary Outcome Measures will be:
Survival time
Total score of the 48-point ALS Functional Rating Scale Revised
Slow Vital capacity (SVC) as a percentage of predicted SVC only if the SVC is performed by the site in a routine-way during standard ALS visit. This test will not be performed for the sole purpose of the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Olesoxime</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive the IMP as add-on to riluzole 50 mg bid orally, 50 mg morning and evening on an empty stomach ie at least 20 min before the meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRO19622</intervention_name>
    <description>2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid</description>
    <arm_group_label>Olesoxime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have completed the 18-month safety and efficacy study of TRO19622 in
             Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole (Protocol TRO19622
             CL E Q 1015-1).

          -  Both the investigator and the patient will decide based on previous good tolerance and
             other clinical grounds whether or not to participate to the open-label extension.

          -  If patients were on anti-vitamin K during the double-blind period, when entering the
             open-label extension, coagulation tests should be monitored in exactly the same
             conditions as if a new anticoagulant treatment was initiated and the dose of
             anti-vitamin K should be adjusted accordingly.

          -  Patients enrolling from this prior safety and efficacy study must:

               -  If female of childbearing age of potential, continue to use adequate birth
                  control methods and have a negative serum pregnancy test at the preceding
                  double-blind protocol termination visit. Male and female partners must agree to
                  use an effective method of birth control during their participation in the trial
                  and for at least 15 days after the last IMP dose. Both partners must use reliable
                  methods of contraception with 2 independent methods. The following measures are
                  acceptable: Hormone contraceptives (e.g. oral contraceptives or comparable
                  methods), intrauterine device, condoms with spermicidal coating or in combination
                  with spermicidal creams, total abstinence or sterilisation performed in the past.

               -  Be able to follow the investigator's instructions and be able to comply with the
                  visit schedule and visit requirements; and

               -  Sign a written informed consent.

        Exclusion Criteria:

        Patients may not participate in this study if they have an ongoing, unresolved, clinically
        significant medical problem (including patients having experienced serious adverse events
        or non-serious, but medically significant adverse events during the preceding safety and
        efficacy study that was assessed to be related to the study medication by the investigator)
        that in the judgment of the investigator would make it unsafe for the patient to
        participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Meininger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitie-Salpetriere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg - Dept Neurology - Herestraat 49</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre SLA Limoges - Service de Neurologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <zip>D-30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry</name>
      <address>
        <city>London</city>
        <zip>SE58AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2011</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophoc Lateral Sclerosis</keyword>
  <keyword>TRO19622</keyword>
  <keyword>Olesoxime</keyword>
  <keyword>Trophos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

